NM
TXMD icon

Newtyn Management’s TherapeuticsMD TXMD Stock Holding History

Newtyn Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-25,000
Closed -$7.55M – 26
2017
Q4 		$7.55M Sell
25,000
-11,000
-31% -$3.06M 1.15% 18
2017
Q3 		$9.52M Hold
36,000
– – 1.54% 17
2017
Q2 		$9.49M Hold
36,000
– – 1.6% 15
2017
Q1 		$13M Buy
36,000
+27,000
+300% +$8.36M 1.95% 12
2016
Q4 		$2.6M Buy
+9,000
New +$2.79M 0.43% 17

Other funds holding TXMD

Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Newtyn Management's TXMD Position: Q1 2018 in Review

Newtyn Management sold out of TherapeuticsMD (TXMD) in Q1 2018, closing a stake of 25,000 shares — an estimated $7.55M sold.

Newtyn Management first reported a position in TXMD in Q4 2016 and held it in 5 quarters. The position peaked at $13M in Q1 2017. 143 funds tracked by Wall St. Rank hold TXMD as of Q1 2018.

  • Newtyn Management reported no remaining TherapeuticsMD position as of Q1 2018 after selling out during the quarter.
  • Newtyn Management sold 25,000 TherapeuticsMD shares in Q1 2018, an estimated $7.55M.
  • Newtyn Management first reported a position in TherapeuticsMD in Q4 2016 and held it in 5 quarters.
  • Newtyn Management's TherapeuticsMD position peaked at $13M in Q1 2017.
  • 143 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2018.

Based on Newtyn Management's 13F filing for Q1 2018, filed 15 May 2018.